Companies:
49,824
Total Market Cap:
139401351959620.41
Global Rank
#32420
Country Rank
#4359
Market Cap
34.94 M
Price
6.36
Change (%)
1.92%
Volume
26,215
Scilex Holding Company's latest marketcap:
34.94 M
As of 07/05/2025, Scilex Holding Company's market capitalization has reached $34.94 M. According to our data, Scilex Holding Company is the 32420th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 34.94 M |
| Revenue (ttm) | 50.71 M |
| Net Income (ttm) | -74,510,000 |
| Shares Out | 5.49 M |
| EPS (ttm) | -14.13 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/12/2025 |
Market Cap Chart
Data Updated: 07/05/2025
Scilex Holding Company's yearly market capitalization.
Scilex Holding Company has seen its market value drop from $173.19 M to $34.94 M since 2021, representing a total decrease of 79.83% and an annual compound decline rate (CAGR) of 36.62%.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/05/2025 | $34.94 M | -54.25% | 32420 |
| 12/31/2024 | $76.36 M | -61.74% | 25071 |
| 12/29/2023 | $199.59 M | -64.61% | 18837 |
| 12/30/2022 | $563.98 M | 225.64% | 11498 |
| 12/31/2021 | $173.19 M | 19691 |
Company Profile
About Scilex Holding Company
Scilex Holding Company specializes in acquiring, developing, and commercializing non-opioid pain management products designed for acute and chronic pain relief.
Commercial Products
- ZTlido (lidocaine topical system) 1.8%: A prescription lidocaine topical product for neuropathic pain associated with postherpetic neuralgia (PHN).
- ELYXYB: A ready-to-use oral solution for acute migraine treatment in adults, with or without aura.
- GLOPERBA: A liquid oral form of colchicine, used to prevent painful gout flares in adults.
Product Pipeline
- SP-102 (SEMDEXA): A novel viscous gel corticosteroid for epidural injections, completing Phase 3 trials for lumbosacral radicular pain (sciatica).
- SP-103 (lidocaine topical system) 5.4%: An advanced formulation of ZTlido for chronic neck and low back pain (LBP), having completed Phase 2 trials.
- SP-104 (low-dose naltrexone): A delayed-release naltrexone hydrochloride capsule, completing Phase 1 trials for fibromyalgia treatment.
Strategic Partnerships
Scilex has collaborations with:
- Oishi and Itochu: For developing lidocaine tape products, including ZTlido and SP-103.
- Lifecore Biomedical, LLC: For clinical trial material manufacturing and development services for SEMDEXA.
Headquarters: Palo Alto, California.
Frequently Asked Questions
-
What is Scilex Holding Company's (SCLX) current market cap?As of 07/05/2025, Scilex Holding Company (including the parent company, if applicable) has an estimated market capitalization of $34.94 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Scilex Holding Company (SCLX) rank globally by market cap?Scilex Holding Company global market capitalization ranking is approximately 32420 as of 07/05/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.